Table 1.

Mechanotransduction's molecular target and related drugs.

Drug	Target	Histology	Current stage	Clinicaltrials.gov identifier (NCT number)	References
Beta-aminopropionitrile (BAPN)	LOX inhibitor	Pancreas, breast and colon cancer	Precinical	–	(154)
Simtuzumab	LOX inhibitor	Pancreas, breast and colon cancer	Phase II	NCT01472198 NCT01479465	(155)
PXS compounds	LOX inhibitor	Breast, oral cancer and hepatocellular carcinoma	Phase I	NCT05109052	(156, 157)
antibody AB0023	LOX inhibitor	Breast and melanoma cancer	Precinical	–	(158)
Tetrathiomolybdate (TM), a copper chelator	LOX inhibitor	Breast, prostate, melanoma, hepatocellular, esophageal, and head neck squamous cell carcinoma cancer	Phase II Phase I Phase II Phase I Phase II	NCT00150995 NCT01837329 NCT00195091 NCT00006332 NCT00176800	(159, 160)
Halofuginone	Smad3 inhibitor	Pancreatic, Hepatocellular carcinoma, Sarcoma	Phase I Phase II	NCT00027677 NCT00064142	(161, 162)
Pirfenidone	TGFβ inhibitor	Non- small cell lung cancer, breast cancer	Phase I/II	NCT04467723 NCT05704166	(163, 164)
Losartan	TGFβ inhibitor	Sarcoma, melanoma, and pancreatic breast cancer	Phase I/II Phase II Phase II Phase I	NCT00880386 NCT05637216 NCT05077800 NCT03864042	(165, 166)
Thiaproline	collagen triple-helix conformation	Mesothelioma	Preclinical	–	(167)
anti-FAP CAR-T	CAF	Lung Cancer	Phase I	NCT01722149	(168–170)
PRTH-101 (DDR1-neutralizing antibody)	collagen receptor discoidin domain receptor 1 (DDR1)	Breast and colon carcinoma	Phase I	NCT05753722	(171, 172)
Oncolytic adenoviral viruses	Relaxin, decorin and MMP expression	Pancreatic, renal cell carcinoma	Preclinical	–	(173–176)
Engineered collagen I-degrading Salmonella typhimurium	Collagen-I degradation	Pancreatic cancer	Preclinical	–	(177)
TRPV4 inhibitor	TRPV4	Colorectal, lung, and gastric cancer	Preclinical	–	(178, 179)
Piezo targeted drugs	Piezo 1	Breast, gastric, bladder, lung, prostate, colon cancer	Precinical	–	(180)